Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

MYSTERIOUS: 6 | Mind Blowing Facts

Denunciantes dicen que las aseguradoras de salud estafan a Medicare para ganar miles de millones

Teresa Ross llevaba meses planteando objeciones en el trabajo cuando sus jefes trajeron a un psicólogo con la esperanza de hacerle cuestionar su propia cordura.

Tribune News Service

UBS Upgrades Rating to Buy for Humana, Raises Price Target To $520

UBS Upgrades Rating to Buy for Humana, Raises Price Target To $520

UBS upgraded its rating of Humana (NYSE:HUM) to Buy with a price target of $520.00, changing its price target from $486.00 to $520.00. Shares of Humana are trading up 2.2% over the last 24 hours, at $458.92 per share. A move to $520.00 would account for a 13.31% increase from…

Whistleblowers say health insurers are scamming Medicare to make billions

Teresa Ross had been raising objections at work for months when her bosses brought in a psychologist hoping to make her question her own sanity.

Tribune News Service

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

This Favorable Sign Appears On Humana's Chart

If history is any guide, there may be good fortune ahead for shares of Humana (NYSE:HUM). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be bullish for the stock.

Here's How Much You Would Have Made Owning Humana Stock In The Last 5 Years

Humana (NYSE:HUM) has outperformed the market over the past 5 years by 1.74% on an annualized basis producing an average annual return of 15.84%. Currently, Humana has a market capitalization of $55.72 billion.

If You Invested $100 In This Stock 10 Years Ago, Here's How Much You Would Have Today

Humana (NYSE:HUM) has outperformed the market over the past 10 years by 5.66% on an annualized basis.

Better Buy for 2022: Humana vs. Clover Health

The rising aging population and the increasing spending on healthcare have been driving the health insurance industry’s growth. So, Humana (HUM) and Clover (CLOV) should benefit. But which of these two stocks is a better buy now? Read more to find out.

inkl

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings For Humana

Expert Ratings For Humana

Analysts have provided the following ratings for Humana (NYSE:HUM) within the last quarter:

Humana Q4 Bottom-Line Beats Expectations, Plans Cost Savings

Humana Q4 Bottom-Line Beats Expectations, Plans Cost Savings

Humana Inc (NYSE: HUM) posts

Humana: Q4 Earnings Insights

Humana: Q4 Earnings Insights

Humana (NYSE:HUM) reported its Q4 earnings results on Wednesday, February 2, 2022 at 06:30 AM. Here's what investors need to know about the announcement.

Humana Earnings Preview

Humana Earnings Preview

Humana (NYSE:HUM) is set to give its latest quarterly earnings report on Wednesday, 2022-02-02. Here's what investors need to know before the announcement. Analysts estimate that Humana will likely report an Earnings Per Share (EPS) of $1.16.

Death Cross Looms Over Humana Investors

Death Cross Looms Over Humana Investors

If history is any guide, there may be trouble ahead for shares of Humana (NYSE:HUM). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish for the stock.

1 … 3 4 5 6

Organisations

Justice Department

Department of Justice

Medicare Advantage

Kaiser Permanente

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Places

364,492 stories

inkl

Read news from The Economist, FT, and more,
with one subscription

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play